Respiratory viral infections by Non-influenza viruses are associated with more adverse clinical outcome in patients with underlying liver disease: a single centre laboratory based study.

Ekta Gupta^{1*}, Abhishek Padhi¹, Kavita Agarwal¹, Krithiga Ramachandran¹, Reshu Agarwal¹, Samba Siva Rao Pasupuleti², Debajyoti Bhattacharyya³, Rakhi Maiwall⁴, Shiv Kumar Sarin⁴.

¹ Department of Clinical Virology, Institute of Liver and Biliary Sciences, New Delhi

² Department of Epidemiology, Institute of Liver and Biliary Sciences, New Delhi

³ Department of Pulmonary Medicine, Institute of Liver and Biliary Sciences, New Delhi

⁴ Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi

* Corresponding Author

Dr Ekta Gupta

Professor and Head

Department of Clinical Virology

Institute of Liver and Biliary Sciences, New Delhi

Email ID : ektagaurisha@gmail.com

Abstract

Background

Respiratory viral infections are an important cause of acute respiratory tract infections. They are caused by both Influenza and non influenza viruses. Respiratory viral infections are known to be associated with severe clinical outcome especially in the critically ill. A constant surveillance is needed for early etiological identification which can help in timely and appropriate management and will further help in prevention of indiscriminate use of antibiotics in patients with viral etiology.

Methods

In this retrospective study, clinical records of all adult liver disease patients with clinically confirmed ARI, whose request for respiratory viral testing were received in the virology

laboratory during September 2016 - March 2019 were reviewed. Respiratory viruses were identified by real time PCR on FilmArray 2.0 instrument (BioFire Diagnostics, Utah, USA) using Respiratory panel as per the manufacturer's instructions.

Results

Of the 603 patients of liver disease with clinically confirmed influenza like illness, over all incidence of respiratory viral infection was 24.3% (n= 147). Infections by non-influenza viruses (87, 59.1%) were more than influenza group of viruses. Mortality was higher in non influenza group (43, 49.4%) as compared to influenza (24, 40%) [p=0.015] being maximum in Rhinovirus, 22 (32.8%). Two peaks were observed in both influenza and non influenza groups, first in the months of January and February and the other one in August and October.

Conclusion

With the emergence of SARS- CoV-2 it has now become imperative for a constant surveillance of the non influenza viruses for early etiological identification of the respiratory viral infection for proper and timely management in the critically ill.

Highlights

- **Patients with liver cirrhosis having Respiratory viral infections have a poor outcome in terms of morbidity and mortality.**
- **Mortality associated with non influenza viruses (NIV) is more as compared to influenza virus infections.**
- **COVID-19 pandemic and higher mortality in NIVs warrants a constant monitoring of respiratory viral infections.**

BACKGROUND

Acute respiratory tract infections (ARI) are usually caused by viruses known as respiratory viral infections (RVI). In adult patients with hospital-acquired pneumonia (HAP) RVI is usually seen in 10-23% of the cases [1]. Disease severity and clinical outcome in RVI varies by the type of virus and underlying co-morbidity [2]. Influenza virus (IVI) infections predominate but other Non-Influenza Viruses (NIV) should also be identified. Number of viruses are included in the NIV category like respiratory syncytial virus, para-influenza virus, cytomegalovirus, human corona viruses, bocavirus, human metapneumovirus and adenovirus [1]. Rhinoviruses are often the most common virus in the NIV group [3]. Corona viruses are also associated with severe ARI and the present ongoing pandemic of SARS CoV-2 further emphasizes the need to identify NIV causing pneumonia [4-6]. Advancement in molecular diagnostics and with the easy availability of Polymerase chain reaction (PCR) for most of the respiratory viruses, identification of viral etiology is faster and easier [7]. Early and exact etiological identification in RVI can help in timely and appropriate management and will further help in prevention of indiscriminate use of antibiotics in patients with viral etiology. Timely and appropriate isolation of infected subjects is also important especially in critical care settings [8, 9]. Underlying co-morbid conditions also influence the clinical outcome in pneumonia patients. Liver disease with cirrhosis is considered as an important co-morbid condition. Influenza outcomes in liver disease patients especially that are critically ill have been well characterised and our previous experience has also shown that liver disease patients with Influenza infection are associated with severe clinical outcome [10]. Though NIV are common in adult patients but are studied very less due to limited attention from the clinical interest, lack of availability of diagnostic tools, vaccine or specific anti-viral treatment.

The recent novel corona virus outbreak has shown that there is a need of regular surveillance for NIV.

Therefore, in this single centre hospital based retrospective study, we tried to look at various NIV and compare with IVI in terms of clinical outcome. In this study, three influenza seasons were included to understand the trend of IVI and NIV in Delhi, a city in the northern part of India.

METHODS

Study group:

In this retrospective study, clinical records of all adult liver disease patients with clinically confirmed ARI, whose request for respiratory viral testing were received in the virology laboratory during September 2016 - March 2019 were reviewed. ARI was defined as per WHO case definition for Influenza like illness as an acute respiratory illness with a measured temperature of $\geq 38^{\circ}\text{C}$ and cough, with onset within the past 10 days [11]. Liver disease was considered in patients having abnormal liver function test parameters. Children < 18 years of age, patients with frank immune-suppression, pregnant females, HIV infected and patients with hepato-cellular carcinoma or any other kind of cancer were excluded from this data. Patient's complete clinical details and follow up investigations were collected from the Hospital information system (HIS).

Ethics statement

The study was reviewed and approved by the Institutional Review Board, Institute of liver and biliary sciences, New Delhi (ILBS). The informed consent was waived by the Institutional Review Board because the study was based on the retrospective analysis of existing clinical data. Patient records/ information was anonymised and de-identified prior to analysis.

Respiratory Virus PCR:

For respiratory virus testing, combined throat and nasopharyngeal swabs in viral transport media (VTM) were collected and transported maintaining appropriate cold chain (2-8°C) to the virology lab within 4 hours of collection. The swabs along with the VTM were vortexed and about 300µl of the sample was taken up for testing for a panel of 21 different respiratory viruses by real time PCR on FilmArray 2.0 instrument (BioFire Diagnostics, Utah, USA) using Respiratory panel as per the manufacturer's instructions [12]. The panel included Adenovirus, Corona virus 229E (CoV229E), Corona virus HKU1 (CoVHKU1), Corona virus OC43 (CoVOC43), Corona virus NL63 (CoVNL63), Human Meta-pneumovirus (MPV), Human Rhinovirus/enterovirus (Rhino/entero), Influenza A (Flu A), Influenza A/H1 (Flu A/H1), Influenza A/H1-2009 (Flu A/H1-2009), Influenza A/H3 (Flu A/H3), Influenza B (Flu B), Middle East Respiratory Syndrome Corona virus (MERSCoV), Para-influenza 1 (PIV1), Para-influenza 2 (PIV2), Para-influenza 3 (PIV 3), Para-influenza 4 (PIV 4), Respiratory syncytial virus (RSV). The FilmArray Respiratory Panel (FilmArray RP) is both FDA-approved and CE IVD-marked. The test is performed in a closed system that requires 5 minutes of hands-on time and 65 minutes of instrumentation time. Several comparison studies between FilmArray and other PCR tests for respiratory viruses showed comparable results [13-15].

Statistical analysis:

Results were expressed as mean and standard deviation (SD) and n (%) for qualitative variables. Association of RVI positivity and outcome with patient's characteristics and biochemical parameters were analyzed using chi-square test/ Fisher's exact or Wilcoxon rank sum test, as appropriate, for univariate comparison. For multivariable analysis, we used logistic regression model, using RVI positivity (positive/negative) or outcome with mortality (present/absent) as the dependent variable. Co-variables tested in the multivariable model were all variables expected to be associated with dependent variable. Results were expressed

as odds ratios (OR) with 95% confidence intervals (CI). A P value of 0.05 or less was considered statistically significant. Statistical analyses were performed using the SPSS software version 25 (IBM Inc., Chicago, IL, USA).

RESULTS

Baseline characteristics:

Six hundred and three patients of liver disease with clinically confirmed ILI were included in the study. In the study population most of them were male (492, 81.6%) and were with a median age of 48 (IQR: 37-59) years (**Table 1**). Overall incidence of RVI in the study group was 24.3%, n=147. The incidence was significantly more in patients requiring ICU care (64.3%, 388), admitted in various wards (31.3%, 189) than coming to the Out-patient department (OPD) (4.3%, 26) (p value: 0.04).

Patients with cirrhosis did demonstrate increase incidence of ILI whether due to RVI or without it, but in univariate analysis it was not significant. However multivariate logistic regression model showed higher RVI occurrence in cirrhotic patients as compared to non-cirrhotic patients (OR 2.98 [1.27-7.00], p=0.012).

There was also significant association of ILI occurrence with the Child–Pugh class A to C. Maximum occurrence seen in CHILD C class (79.5%, 303) as compared to CHILD B (13.9%, 53) and A (6.5%, 25), p value : 0.006. This trend was similar in both the groups with RVI and without RVI. Mortality was much higher in the RVI group (52.3%, 77) as compared to overall (34.4%, 208) and without RVI (28.7%, 131) (p value: 0.38).

Comparison of RVI cases due to influenza virus infections (IVI) and Non influenza virus infections (NIVI)

Out of 147 patients with RVI, infections by non-influenza viruses (NIV) (87, 59.1%) were more than influenza group of viruses (IVI) including influenza A (H1N1) pdm 2009, Influenza A (H3N2) and Influenza B (60, 40.8%) as depicted in figure 1.

In 8 (5.4%) dual viral infections were also seen, mostly with Rhino/entero group of viruses (Table 2).

In the NIV group, Rhino/ Entero viruses were commonest (41, 27.8%) followed by RSV (17, 11.5%).

Differences among IVI and NIVI groups are presented in Table 3.

Both IVI and NIVI were more frequent in males as compared to females ($p=0.029$) and in patients who required ICU care ($p<0.001$).

Differences among the groups were significant in patients with cirrhosis.

Significant differences were seen in the outcome in both the groups, mortality was higher when RVI was due to NIVI than IVI ($p=0.015$).

Both the groups showed increased association with the CHILD category, being higher in the category C patients. MELD score was higher in the NIVI group (0.031). This could be the reason for more mortality in this group. The liver function tests (ALT,AST) were significantly more deranged in the IVI group than NIVI.

Respiratory Viral Infections and seasonality:

We retrospectively analysed the data from the laboratory archive and the time line included was from September 2016 till March 2019. Delhi lies in the Northern parts of the [Indian Subcontinent](#) with 3 specific seasons: summer(March to June), monsoon(July –September), and winter(October –February). Winter seasons starts from October and lasts till February. In the present study, 3 winter seasons were considered. The distribution of various influenza and non-influenza viruses in different seasons is depicted in Figure 2.

Total number of Influenza and non-influenza cases seen in March-September were 62, 42.1% (IVI: 24, NIVI:38) lesser than 85 (57.8%) (IVI :39,NIVI:46) seen in October-February. Two peaks could be clearly seen first in the months of January and February and the other one in August and October.

RVI Co-infections with other pathogens:

Out of 147 patients, in 87 patients investigations for a bacterial and fungal etiology that was done at baseline were available (Figure 2).

In 44 (50.5%) patients also showed bacterial/fungal co-infection along with RVI. 32 (23.8%) patients with bacterial co-infection, 12 (37.5%) with fungal and 3 (6.3%) with both bacterial and fungal (3, 6.3%) was seen. Co-infections were maximum with Influenza group of viruses (19, 40.4%) followed by Rhino/entero group of viruses (12, 25.5%) among these 47 co-infected patients.

Development of subsequent/ secondary bacterial infection was also observed in these 147 patients. Secondary bacterial infection was considered when lower respiratory tract sample (sputum, BAL) became positive for a bacterial isolate after RVI detection up to a week in the patients negative for the respective bacterial infection initially. Overall secondary bacterial

co-infections were seen in 15 (10.2%) patients which were mostly seen after Influenza viral infections 6 (40%) and Rhino viral infections 6 (40%) as compared to other RVI etiology.

Association of respiratory viruses and mortality:

Overall 67 deaths were observed in the RVI positive patients. Mortality was higher in NIVI group (43, 49.4%) as compared to IVI (24, 40%) [$p=0.015$] being maximum in Rhinovirus, 22 (32.8%) as shown in Table 4.

On comparing the RVI cases that died ($n=67$) with those who survived ($n=80$) a significant association was seen in the univariate analysis with the age of the patient ($p=0.03$), more seen in the age group 46-60 years of age, all the deaths occurred in the patients who were admitted and required the ICU care ($p<0.001$), with the underlying cirrhosis of the liver ($p<0.001$), bilirubin level ($p<0.001$), creatinine levels ($p<0.001$) and platelet count ($p<0.001$) [Table 5]. However on multivariate analysis, no association of outcome in terms of mortality was found with analyzed demographic and biochemical parameters.

DISCUSSION

To our knowledge, the present study is the first descriptive study on various respiratory viruses in adult population with liver disease. Influenza and non-influenza viruses have also been compared in terms of their clinical presentation and clinical outcome. Seasonality of the occurrence of these RVIs is also studied.

The present study highlighted that occurrence of RVI is more commonly seen in patients who required intensive care treatment, with higher Child Pugh score and more with cirrhosis. RVI occurrence was higher in CHILD category C as compared to lower categories. Overall prevalence seen in our study of RVI in liver disease patients was 24.3% which is similar to

earlier studies from our institute where overall prevalence of RVIs was found in 22.2% cirrhotic patients with pneumonia [16] .

Apart from IV other NIV should also be studied especially in patients requiring ICU care as NIV are more common in them. Earlier these groups of viruses were not considered to be causative for pneumonia but recent literature cites etiological role of rhino virus group in the causation of pneumonia in adults [3, 17]. In the present study rhino viruses were also associated with mortality as seen in 16 cases, though all the 16 cases were from ICU and multiple factors contribute to mortality. RVI in isolation cannot be contributory in mortality. Furthermore SARS-CoV-2 has established that NIV are an important cause of viral pneumonia and has necessitated the diagnosis of RVIs at the earliest.

Influenza A viruses were associated with more adverse outcome has been shown by earlier publications [18]. Influenza A is the greatest cause of mortality and morbidity among the viral types of pneumonia [19]. In our study influenza group of viruses accounted to 40.8% of the total RVIs. Few studies done in our center have shown the prevalence of influenza virus and its impact on the clinical outcome of cirrhotic patients [16], [20]. Interestingly in the present study mortality associated with NIV (49.4%) was more than IVIs (40%). This highlights the importance of constant surveillance of NIVs especially in the critically ill.

In India, multisite epidemiological and virological influenza surveillance established previously reported peak influenza activity to be associated with rainy season and a secondary peak in the winter months [21]. Annual Influenza vaccination is recommended in patients with underlying liver disease especially cirrhotic group. Both IV and NIV were seen peaking in Delhi during monsoon period in the months of August – October and then again

from December to February during the winter hence in Delhi a pre monsoon influenza vaccination strategy must be established. Our findings are consistent with previously reported studies where a monsoon peak followed by minor peak in winter was observed in Delhi [21]. Mixed viral-bacterial infections may be associated with an increased risk of mortality [22]. RVI alters respiratory flora and making the host more susceptible to secondary bacterial infections. Secondary bacterial infections were also quite common with Rhino associated RVI [23]. In the present study also secondary bacterial infections were seen mostly in Rhino associated RVI (40%).

Viral infections predispose patients to secondary bacterial infections, which often have a more severe impact on patients with cirrhosis. As the host immune system are already compromised in patients with cirrhosis it is therefore imperative to identify ARI caused by viruses in them and where ever a definitive treatment is available to initiate so that secondary bacterial infection and prolonged stay of the patient can be prevented.

Cirrhotic patients, especially the higher risk groups, should be targeted for preventive measures such as influenza and pneumonia vaccination as well as early and effective outpatient management of those who have contracted ARI in order to prevent costly and high-risk hospital admissions.

Although the composition of the gastrointestinal microbiome is largely influenced by dietary patterns, respiratory viral infections could also contribute, along with other stress inducers such as broad-spectrum antibiotics exposure and chronic inflammation.

Using animal models of pulmonary infections by influenza and respiratory syncytial virus (RSV), multiple groups have shown that the gut microbiome is clearly impacted by respiratory viral infections, despite the lack of detectable respiratory virus in the gut [24–28].

Gut microbiome alterations influence the severity outcome in patients with cirrhosis hence all the more essential to early diagnosis and treat any respiratory viral infection.

Previous studies have established the role of multiplex PCR panels as more rapid and sensitive than routine culture and antigen detection methods [29-36]. Although multiplex panels are rapid and accurate, the high cost to the laboratory and patient may limit their use in resource-limited settings of developing nations.

Our study does have few limitations. Firstly, it is a single center laboratory based study where majority are known patients with liver ailments. Secondly The lack of a control population with no respiratory symptoms is another limitation that precludes any conclusion on the pathogenicity of NIRV. Despite these minor limitations our study adds significantly to the literature by contributing to better characterization of the burden of NIV in adult patients with liver cirrhosis.

Acknowledgement

The authors would like to thank Mr. Sandeep Singh for compiling the data and all the technical staff of the Department of Clinical Virology, Institute of Liver and Biliary Sciences, New Delhi

CONCLUSION

With the on going COVID-19 pandemic the role of NIV as a major cause of viral pneumonia has come into lime light. The otherwise neglected NIV should be evaluated and studied in more details to understand their pathophysiology as a cause of RVI in cirrhotic patients.

CONFLICT OF INTEREST

None

DATA AVAILABILITY STATEMENT

Readers may contact the authors for accessing data used in this study.

AUTHORSHIP CONTRIBUTION STATEMENT

EG : Writing - original draft, Writing - review & editing, Methodology, Supervision, Project administration. **AP** - Writing - review & editing **KA**: Resources, Methodology, Data analysis. **KR, RA,SSRP** : Data curation. **DB, RM**: Writing - review & editing, Supervision. **SKS** : Project administration, Supervision, Writing - review & editing.

References

1. Hong HL, Hong SB, Ko GB, et al. Viral infection is not uncommon in adult patients with severe hospital-acquired pneumonia. *PLoS One* 2014; 9:e95865.
2. Ishiguro T, Kagiya N, Uozumi R, et al. Clinical Characteristics of Influenza-Associated Pneumonia of Adults: Clinical Features and Factors Contributing to Severity and Mortality. *Yale J Biol Med.* 2017;90(2):165–81.
3. Jain S, Self WH, Wunderink RG, et al. Community acquired pneumonia requiring hospitalization among U.S. adults. *N Engl J Med.* 2015;373(5):415–27.

4. Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives [published online ahead of print, 2020 Mar 29]. *Int J Antimicrob Agents*. 2020;105951. doi:10.1016/j.ijantimicag.2020.105951
5. Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. *Sci China Life Sci*. 2020;63(3):457–60. doi:10.1007/s11427-020-1637-5
6. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med*. 2020;382(13):1199–207. doi:10.1056/NEJMoa2001316
7. Artika IM, Wiyatno A, Ma'roef CN. Pathogenic viruses: Molecular detection and characterization [published online ahead of print, 2020 Jan 30]. *Infect Genet Evol*. 2020;81:104215. doi:10.1016/j.meegid.2020.104215
8. Hellewell J, Abbott S, Gimma A, et al. Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. *Lancet Glob Health*. 2020;8:e488–96.
9. Chen W, Wang Q, Li YQ, et al. Early containment strategies and core measures for prevention and control of novel coronavirus pneumonia in China. *Chin J Prev Med*. 2020;54: 1–6
10. Papic N, Pangercic A, Vargovic M, Barsic B, Vince A, Kuzman I. Liver involvement during influenza infection: perspective on the 2009 influenza pandemic. *Influenza Other Respir Viruses*. 2012;6(3):e2–e5.
11. WHO. Global Epidemiological Surveillance Standards for Influenza. (Available from: http://www.who.int/influenza/resources/documents/WHO_Epidemiological_Influenza_Surveillance_Standards_2014.pdf)
12. Poritz MA, Blaschke AJ, Byington CL, Meyers L, Nilsson K, et al. FilmArray, an Automated Nested Multiplex PCR System for Multi-Pathogen Detection:

- Development and Application to Respiratory Tract Infection. PLoS ONE. 2011; 6(10): e26047.
13. Wahrenbrock MG, Matushek S, Boonlayangoor S, Tesic V, Beavis KG, Charnot-Katsikas A. Comparison of Cepheid Xpert Flu/RSV XC and BioFire FilmArray for detection of influenza A, influenza B, and respiratory syncytial virus. J Clin Microbiol. 2016;54(7):1902–3.
14. Andersson ME, Olofsson S, Lindh M. Comparison of the FilmArray assay and in-house real-time PCR for detection of respiratory infection. Scand J Infect Dis. 2014; 46(12):897-901.
15. Renaud C, Crowley J, Jerome KR, Kuypers J. Comparison of FilmArray respiratory panel and laboratory-developed real-time reverse transcription–polymerase chain reaction assays for respiratory virus detection. [Diagn Microbiol Infect Dis](#). 2012;74(4):379–83.
16. Spectrum of respiratory viral infections in liver disease patients with cirrhosis admitted in critical care unit. Bajpai V, Gupta E, Mitra LG, Kumar H, Maiwall R, Soni KD, Gupta A. J Lab Physicians. 2019 Oct-Dec;11(4):356-360. doi: 10.4103/JLP.JLP_6_19.
17. Katsurada N, Suzuki M, Aoshima M, et al. The impact of virus infections on pneumonia mortality is complex in adults: a prospective multicentre observational study. *BMC Infect Dis*. 2017;17(1):755
18. Premkumar M, Devurgowda D, Dudha S, et al. A/H1N1/09 Influenza is Associated with High Mortality in Liver Cirrhosis. J Clin Exp Hepatol. 2019;9(2):162–170. doi:10.1016/j.jceh.2018.04.006

19. Freeman AM, Leigh, Jr TR. Viral Pneumonia. [Updated 2019 Dec 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK513286/>
20. Influenza A/H1/N1/09 infection in patients with cirrhosis has a poor outcome: a case series. Bal CK, Bhatia V, Kumar S, Saini D, Khillan V, Gupta E, Rathor N, Choudhury A, Kumar N, Daman R, Sarin SK. Indian J Gastroenterol. 2014 Mar;33(2):178-82. doi: 10.1007/s12664-014-0443-5. Epub 2014 Jan 29. PMID: 24470044
21. Chadha MS, Potdar VA, Saha S, Koul PA, Broor S, Dar L, *et al.* Dynamics of influenza seasonality at sub-regional levels in India and implications for vaccination timing. PLoS One 2015;10 :E0124122
22. Quah, J., Jiang, B., Tan, P.C. *et al.* Impact of microbial Aetiology on mortality in severe community-acquired pneumonia. BMC Infect Dis. 2018;18:451 <https://doi.org/10.1186/s12879-018-3366-4>
23. Arnason J, Jamieson K, Kooi C, et al. Pre-existing human rhinovirus infection modulates host response to secondary bacterial infections. Allergy Asthma Clin Immunol. 2014;10(Suppl 1):A57
24. Wang J, Li F, Wei H, Lian Z-X, Sun R, Tian Z. Respiratory influenza virus infection induces intestinal immune injury via microbiota-mediated Th17 cell-dependent inflammation. J Exp Med. 2014;211:2397–410.
25. Deriu E, Boxx GM, He X, Pan C, Benavidez SD, Cen L. Influenza Virus Affects Intestinal Microbiota and Secondary Salmonella Infection in the Gut through Type I Interferons. PLoS Pathog. 2016;12:e1005572.

26. Bartley JM, Zhou X, Kuchel GA, Weinstock GM, Haynes L. Impact of age, caloric restriction, and influenza infection on mouse gut microbiome: an exploratory study of the role of age-related microbiome changes on influenza responses. *Front Immunol.* 2017; 8:1164.
27. Yildiz S, Mazel-Sanchez B, Kandasamy M, Manicassamy B, Schmolke M. Influenza A virus infection impacts systemic microbiota dynamics and causes quantitative enteric dysbiosis. *Microbiome.* 2018;6:9.
28. Groves HT, Cuthbertson L, James P, Moffatt MF, Cox MJ, Tregoning JS. Respiratory disease following viral lung infection alters the murine gut microbiota. *Front Immunol.* 2018;9:182.
29. Couturier MR, Barney T, Alger G et al. Evaluation of the FilmArray® respiratory panel for clinical use in a large children's hospital. *Journal of Clinical Laboratory Analysis.* 2013;27(2):148-54.
30. Hammond SP, Gagne LS, Stock SR et al. Respiratory virus detection in immunocompromised patients with FilmArray Canadian Respiratory Journal 5 respiratory panel compared to conventional methods. *Journal of Clinical Microbiology.* 2012;50(10):3216 –21.
31. Layman CP, Gordon SM, Elegino-Steffens DU, Agee W, Barnhill J, Hsue G. Rapid multiplex PCR assay to identify respiratory viral pathogens: moving forward diagnosing the common cold. *Hawaii Journal of Medicine & Public Health.* 2013;72(9):24–6.
32. Loeffelholz MJ, Pong DL, Pyles RB et al. Comparison of the FilmArray respiratory panel and Prodesse real-time PCR assays for detection of respiratory pathogens. *Journal of Clinical Microbiology.* 2011;49(12):4083–8.

33. Pierce VM, Elkan M, Leet M, McGowan KL, Hodinka RL. Comparison of the Idaho Technology FilmArray system to real-time PCR for detection of respiratory pathogens in children. *Journal of Clinical Microbiology*. 2012;50(2):364–1.
34. Rand KH, Rampersaud H, Houck HJ. Comparison of two multiplex methods for detection of respiratory viruses: FilmArray RP and xTAG RVP. *Journal of Clinical Microbiology*. 2011;49(7):2449–53.
35. Soccia PM, Aubert JD, Bridevaux PO et al. Upper and lower respiratory tract viral infections and acute graft rejection in lung transplant recipients. *Clinical Infectious Diseases* 2010;51(2):163–70.
36. Ruggiero P, McMillen T, Tang YM, Babady NE. Evaluation of the BioFire FilmArray respiratory panel and the GenMark eSensor respiratory viral panel on lower respiratory tract specimens. *Journal of Clinical Microbiology*. 2014;52(1):288–90.

Table 1: Baseline characteristics of the study population

S. No	Variable	Total (n = 603) n (%)	With RVI (n=147) n (%)	Without RVI (n=456) n (%)	p- value
1	Age (in years)				0.16
	18-30	82(13.5)	26 (17.7)	56 (12.3)	
	31-45	185(30.6)	47 (31.9)	138 (30.2)	
	46-60	209(34.6)	50 (34.0)	159 (34.8)	
	>60	127(21.06)	24 (16.3)	103 (22.6)	
2	Sex				0.63
	Male	492(81.6)	118 (80.2)	374 (82)	
	Female	111(18.40)	29 (19.7)	82 (17.9)	
3	Admission Type				0.04
	ICU	388(64.3)	101 (68.7)	287 (62.9)	
	Ward	189(31.3)	36 (24.5)	153 (33.5)	
	OPD	26(4.3)	10 (6.8)	16(3.51)	

4	Cirrhosis Present Absent	381(63.1) 222(36.8)	99 (67.3) 48 (31.2)	282 (61.8) 174 (38.1)	0.20
5	OUTCOME Expired Stable	208(34.4) 395(65.5)	77 (52.3) 70 (47.6)	131 (28.7) 325 (71.2)	0.38*
6	Child-Pugh class A B C	n=381 25(6.5) 53(13.9) 303(79.5)	n=99(25.9) 13 (13.1) 8 (8.0) 78 (78.7)	n=282(74.0) 13 (4.6) 45 (15.9) 224 (79.4)	0.006*
7	MELD	n= 350 29.24±8.57	n=79 30.39±8.29	n=271 29.04±8.62	0.185
8	Total Bilirubin	9.85±10.13	10.34±10.67	9.72±9.95	0.715
9	AST	253.72±1342.87	249.39±1320.31	251.88±1338.34	0.557
10	ALT	104.08±343.84	103.56±395.10	103.34±323.07	0.094
11	ALP	114.93±94.22	112.09±90.550	115.51±94.95	0.871
12	GGT	73.63±146.367	71.65±119.62	74.04±152.86	0.502
13	Urea	83.63±164.03	76.75±53.06	86.57±184.52	0.853
14	Creatinine	1.88±4.24	1.57±1.42	1.99±4.76	0.534
15	Hemoglobin	8.85±3.68	9.22±6.51	8.75±2.09	0.796
16	Platelet count	101.86±87.50	104.46±93.94	100.93±85.56	0.996

Table 2: Types of Respiratory Viruses causing infection in the study group.

Respiratory viruses	n (%)
Flu A/H1-2009	31 (21.1)
Flu A /H3	12 (8.1)
Flu B	9 (6.1)
RSV	15(10.2)
MPV	8(5.4)
PIV 1	1 (0.6)
PIV3	7 (4.7)
PIV 4	4 (2.7)
Rhino/entero	37 (25.1)
Adenovirus	6 (4.1)
Coronavirus*	9 (6.1)

Influenza A (H1N1) pdm 2009+ Rhinovirus	4(2.7)
Influenza A (H1N1) pdm 2009+ Metapneumovirus	2(1.3)
Influenza B+ RSV	2(1.3)
Total	147(100)

Abbreviations:

Human Meta-pneumovirus (MPV), Human Rhinovirus/enterovirus (Rhino/entero), Influenza A (Flu A), Influenza A/H1-2009 (Flu A/H1-2009), Influenza A/H3 (Flu A/H3), Influenza B (Flu B), Para-influenza 1 (PIV1), Para-influenza 3 (PIV 3), Para-influenza 4 (PIV 4), Respiratory syncytial virus (RSV).

*Corona virus included : corona virus 229E (CoV229E), corona virus HKU1 (CoVHKU1), corona virus OC43 (CoVOC43), corona virus NL63 (CoVNL63).

Table 3: Comparison between Respiratory Viral Infections (RVI) due to Influenza virus infection (IVI) and Non influenza Viral Infections (NIVI).

S. No.	Variable	Total (n = 147) n (%)	IVI (n=60) n (%)	NIVI (n=87) n (%)	P value
1.	Age (in years)				
	0-30	26(17.68)	9 (15%)	17(19.54%)	0.854
	31-45	47(31.97)	21 (35%)	26(29.89%)	
	46-60	50(34.01)	20(33.33%)	30(34.48%)	
	>60	24(16.32)	10(16.67%)	14(16.09%)	
2.	Sex				
	Male	118(80.27)	43(71.67%)	75(86.21%)	0.029
	Female	29(19.72)	17(28.33%)	12(13.79%)	
3.	Admission Type				
	ICU	101(68.70)	32(53.33%)	69(79.31%)	0.000
	Ward	36(24.48)	18(30%)	18(20.69%)	
	OPD	10(6.80)	10(16.67%)	0(0%)	

4.	Cirrhosis Present Absent	99(67.34) 48(30.61)	35(58.3) 25(41.6)	64(73.5) 23(26.4)	0.057
6.	OUTCOME Expired Stable	67(45.5) 80(54.4)	24(40%) 46(76.6%)	43(49.4%) 34(39.1%)	0.015
7.	CHILD scoring A B C	n= 99 13 (13.1) 8 (8.0) 78 (78.7)	n= 37 7 (18.9%) 5 (13.5%) 25 (67.5%)	n=62 6(9.6%) 3 (4.8%) 53(85.4%)	0.018
8.	MELD	n= 79 30.39±8.29	n=27 27.75±9.77	n=52 31.08±7.50	0.031
9.	CTP	11.88±2.07	11.58±2.69	11.85±1.72	0.131
10.	Total Bilirubin	10.34±10.67	6.57±8.33	12.90±11.52	0.370
11.	AST	249.39±1320.31	392.54±2094.06	165.94±280.07	0.000
12.	ALT	103.56±395.1	147.80±621.31	77.38±106.30	0.010
13.	ALP	112.09±90.55	129.71±117.46	101.08±68.57	0.669
14.	GGT	71.65±119.62	97.95±159.93	54.01±82.90	0.067
15.	Urea	76.75±53.06	67.91±55.76	77.75±48.72	0.057
16.	Creatinine	1.57±1.42	1.49±1.54	1.54±1.30	0.023
17.	Hemoglobin	9.22±6.51	9.16±2.68	9.22±8.48	0.247
18.	Platelet count	104.46±93.94	94.91±71.94	112.15±106.84	0.004

Table 4: Viral etiology wise mortality in the RVI cases

Respiratory viruses	Mortality in patients [n =67] n (%)
Influenza A (H1N1) pdm 2009	13 (19.4%)
Influenza A (H3N2)	7 (10.4%)
Influenza B	4 (5.9%)
RSV	9 (13.4%)
MPV	4 (5.9%)
PIV 1	1 (1.4%)
PIV 3	1 (1.4%)
Rhinovirus	22 (32.8%)
Adenovirus	2 (2.9%)
Coronavirus	4 (5.9%)

Table 5: Association of mortality in RVI positive cases with various clinical and laboratory parameters.

S. No	Variable	Mortality(n=67)	No Mortality(n=80)	p-value
1.	Age (in years)			0.03
	18-30	4 (5.9%)	22 (27.5%)	
	31-45	19 (28.3%)	28 (35%)	
	46-60	27 (40.2%)	23 (28.7%)	
	>60	17 (25.3%)	7(8.7%)	
2.	Sex			0.25
	Male	53 (79.1%)	65 (81.2%)	
	Female	14 (20.8%)	15 (18.7%)	
3.	I/W/O			0.00
	ICU	67 (100%)	34 (42.5%)	
	Ward	0 (0%)	36 (45%)	
	OPD	0 (0%)	10(12.5%)	
4.	Cirrhosis			0.00
	Present	60 (89.5%)	39 (48.7%)	
	Absent	7 (10.4%)	41 (51.2%)	
6	Total Bilirubin	12.91±10.78	4.73±7.53	0.00

7.	AST	182.49±322.66	395.27±2238.65	0.00
8.	ALT	76.07±103.61	160.61±666.38	0.05
9.	ALP	111.21±107.64	116.47±75.89	0.40
10.	GGT	88.70±148.03	56.61±69.03	0.95
11.	Urea	95.17±56.15	44.51±32.23	0.04
12.	Creatinine	1.80±1.46	1.03±1.01	0.00
13.	Hemoglobin	8.01±1.74	9.78±2.62	0.73
14.	Platelet count	70.18±47.34	143.86±118.99	0.06

Figure 1 Flowchart of patients hospitalized with influenza-like illness, and viruses detected in respiratory sample

Figure 2 Seasonality of respiratory viral infections